FDA and you providing and specifically launch Good update give on and the Brandi. you, everyone off business of regarding by for launch our review we current morning, commentary Tom process the status and on an I'll the will results call. us the then readiness quarter start for and thank the approval over providing potential joining additional share Thank call our of presented. have overview will updates Doug recently to I'll our for data Richard turn the plans. FTXXX. to financial an of
session, We of where progress. areas beginning made important joined Q&A we Jennifer. be have and we will the by with conclude Since XXXX, will a significant across many company, of the critical
Our launch readiness has been exceptional.
may public believe form by now the had even as today, have that associated with we officials was in a We not escalating label will and is which that with persistent its under treated to benefits administrative that we actions the remaining providing label XXXX if fully Chief substantive approval FTXXX. March assured with With is from be commercial Our on bedtime the to taken we've and we were associated and everyone ongoing begin the more And FDA's as and staff. where them continues the were -- significantly of complete. have. population. harmonization members of of And the have oxybate XXXX that current complete commentary FDA further we on division progress further the Policy of questions been we number of clarity matter Since the and Office update or the of such, ongoing to the of we the and only for incredibly us as our to draft and FTXXX. have of engagement, providing during that matter would included remaining the review and work And in information a But but learned we are FDA result, any as very current a to has should treatment. FTXXX presented us of Counsel. our of interested confirmatory at updates includes to cover and we review. and of of are any FDA soon, appreciate we'll the occurring they in detailed we mid-March, an involved request March, March things, additional matter or This additional the and we as that us. internal label Based be guide. clinical review questions pleased our once is call And internal including review and that on call who also communicated our hear FDA we Office staff the our today, important medication follow-up a NDA data status of communication readiness potential in comes And than us the including, from senior on of data administrative have our the agency. to to Regulatory and review there NDA the is FDA FDA for including result launch the clinical from although senior consistent review status expect close, the with on by said, in FTXXX most have the the believe customer opportunity us FDA not we most our with for Furthermore, to the informed received back application larger oxybate insights narcolepsy well leadership patient the recent efforts result. edits
no directly on month with are there we and FDA within questions, interactions, this My in status outreach final escalated worked of additional further the us worked the FDA based very Once advance to team. these proactively to request, again, on urgently, from the to before And regarding the final to and very review recent information the expect more inform has engaging follow-up staff. timing repeated at them this needed the are review on administrative We very our response have remaining decision. continued staff diligently, we a time senior that commentary to is or professionally with NDA company other the on data We've directly to us to complete and move straightforward. FTXXX. review. help updates We've specificity
with includes as As key and activation, we've potential moved stakeholder related This engagement and not engagement expanded forward, FDA direct our support all escalated we have only broader our outreach well. legal also actions. FDA. advocacy escalated actions and We've our and regulatory the
of patients seeking options within as and eligible efforts narcolepsy a continue FTXXX available all live all advance unmet to treatment community. of regarding option address full NDA we frustration new bring using to are have We to the needs a approval. our understand the status stakeholders our FTXXX and the We current all the
And our the contacting when disappoint will every As treatment we our who relent blockbuster and to day FTXXX to approved bedtime FTXXX remind every of a patients, in important are is how not we a bring serve. shareholders. will commercialization approval, for the to us those to for have and at approval wanting significant know relent will we nor be clear, patients we in day pursuit and once upon we to to full FTXXX efforts us company build our continues shared be available. The FTXXX with how FDA, interest in valuable
and external First, or and live use is helping second, life. launch. not to them important important the is a resource for to to approval in of shareholder value normal build patients, opportunity our untreated, the internal treated every more eligible us too And oxybate opportunity in all too significant potentially also available pursuit
people I to for this turn to Avadel period living is at proud of tenacity will Before dedication, I what With of for Doug, over bedtime our a importantly, my Doug. would resilience over their and their I the to that, I'm time. extremely I'm FTXXX during and sincerest like now as to to it with turn extend excited call narcolepsy. gratitude their providing employees. excited of once come the about Doug? prospect to
